We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.
- Authors
KANA HAYASHI; KOTARO TOKUI; MINEHIKO INOMATA; KENJI AZECHI; ISAMI MIZUSHIMA; NAOKI TAKATA; CHIHIRO TAKA; SEISUKE OKAZAWA; KENTA KAMBARA; SHINGO IMANISHI; TOSHIRO MIWA; RYUJI HAYASHI; SHOKO MATSUI; SATOSHI NOMURA; KAZUYUKI TOBE
- Abstract
Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.
- Subjects
LUNG cancer treatment; PEMBROLIZUMAB; MONOCLONAL antibodies; CARCINOMA; CARBOPLATIN; ANTINEOPLASTIC agents
- Publication
In Vivo, 2021, Vol 35, Issue 3, p1687
- ISSN
0258-851X
- Publication type
Case Study
- DOI
10.21873/invivo.12428